JGJulien Van Gils

Julien Van Gils

*This is an algorithmically generated author record based on publicly available information.

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julien Van Gils has a total of 806 co-authors. Here are the top co-authors by number of shared publications:

  • Marlène Rio

    Fédération de Génétique, Hôpital Necker-Enfants Malades

    7 shared publications
  • Bertrand Isidor

    Service de génétique médicale, Unité de génétique clinique, CHU Hôtel Dieu, 1 place Alexis Ricordeau, Nantes, France

    6 shared publications
  • Jonathan Levy

    Department of Genetics, APHP-Robert Debré University Hospital, Paris, France

    6 shared publications
  • Anne-Sophie Denommé-Pichon

    Université Bourgogne Europe, CHU Dijon Bourgogne, Laboratoire de Génomique Médicale, FHU-TRANSLAD, Centre de recherche Translationnelle en Médecine moléculaire - Inserm UMR1231 équipe GAD, Dijon, France

    5 shared publications
  • Boris Keren

    Département de génétique médicale, Hôpital Pitié-Salpêtrière, AP-HP.Sorbonne Université, Paris, France

    5 shared publications
  • Cyril Mignot

    Département de génétique médicale, Hôpital Pitié-Salpêtrière, AP-HP.Sorbonne Université, Paris, France

    5 shared publications

Latest Publications

  • Syndrome de Rubinstein-Taybi : Caractérisation des profils épigénétiques pour l’étude des mécanismes moléculaires de la pathologie

    by Julien Van-Gils

    Rubinstein-Taybi syndrome : Characterization of epigenetic profiles to study the molecular mechanisms of the disease: Le syndrome de Rubinstein-Taybi (SRT) est une anomalie génétique du développement, avec déficience intellectuelle, anomalies typiques de la face et des extrémités et multiples anomalies congénitales. CREBBP et EP300, les deux gènes impliqués dans le déterminisme du SRT, sont des coactivateurs transcriptionnels avec un domaine catalytique lysine acétyl transférase et jouent un rôle majeur dans le remodelage de la chromatine. L’altération de l’acétylation des histones est associée à une modulation inappropriée de l’expression génique, en particulier au cours du développement. Le SRT est un modèle de trouble épigénétique du neurodéveloppement. Chez les patients SRT, le lien fonctionnel entre l'acétylation des histones et les profils transcriptomiques au cours de la différenciation neuronale n’est pas connu. Nous avons dérivé des cellules souches pluripotentes induites de patients SRT porteurs d'une mutation CREBBP récurrente connue pour inactiver le domaine KAT. Après différenciation en neurones corticaux et pyramidaux, nous avons comparé les acétylomes par LS-MS/MS et les transcriptomes par RNA-seq à des cellules dérivées de donneurs sains. Aucune différence morphologique n'a été observée au cours de la différenciation neuronale entre les patients SRT et les témoins, mais la maturation neuronale semble être affectée au niveau moléculaire. Nous avons identifié 25 marques d’acétylation des histones spécifiquement altérées dans le SRT. Les histones H2B et H3 sont les plus impactées. L'altération de l'acétylation se maintient tout au long de la différenciation neuronale pour la majorité de ces 25 marques d'histones. Les analyses transcriptomiques ont montré une étape critique du processus de différenciation entre progéniteurs neuronaux et neurones immatures, avec une nette augmentation des gènes différentiellement exprimés dans le SRT par rapport aux contrôles. Ces analyses ont noté un impact sur les gènes impliqués dans la différenciation neuronale, illustrant un délai de maturation neuronale dans le SRT. L'analyse du transcriptome sur les fibroblastes des mêmes patients a mis en évidence une répression transcriptionnelle au sein des voies liées à la différenciation neuronale et au guidage des axones. Cela nous a permis d'identifier 8 biomarqueurs potentiels qui pourraient définir une signature transcriptomique du SRT dans les fibroblastes.L'identification des mécanismes physiopathologiques reste un enjeu majeur pour une compréhension des troubles cognitifs chez les patients. Nous avons établi la première cartographie de l'acétylation des histones dépendante de CBP chez l'Homme. L'analyse des fibroblastes reflète les altérations observées au niveau neuronal, en faisant un tissu de choix pour le développement de biomarqueurs pour le diagnostic dans le soin courant. Cette étude ouvre de nouvelles perspectives dans la définition de biomarqueurs épigénétiques pour le SRT, dont la méthodologie pourrait être étendue à toutes les chromatinopathies.

  • Correction: Comprehensive analysis of CNOT3-related neurodevelopmental disorders: phenotypic and genotypic characterization

    by Camille Engel, Michaela Rendek, Jessica Assoumani, Emanuela Argilli, Francesca Ariani, Anne-Laude Avice-Denizet, Emilia K. Bijlsma, Pierre Blanc, Lucia Pia Bruno, Bert Callewaert, et al.

  • Top Cited Papers
    Open Access

    Systematic analysis of snRNA genes reveals frequent RNU2-2 variants in dominant and recessive developmental and epileptic encephalopathies

    by Elsa Leitão, Amandine Santini, Benjamin Cogne, Miriam Essid, Maria Athanasiadou, Christy W. LaFlamme, Pierre Marijon, Virginie Bernard, Kevin Jousselin, Nicolas Chatron, et al.

    Small nuclear RNAs (snRNAs) are essential components of the spliceosome. De novo variants in snRNA genes RNU4-2 (ReNU syndrome), RNU5B-1 and RNU2-2 have been linked to dominant neurodevelopmental disorders (NDDs), revealing a large unexpected contribution of noncoding RNA genes to genetic diseases. Here, through international collaborations, we analyze systematically 200 potentially functional snRNA genes in a French cohort of 34,329 people with rare disorders. We report RNU2-2 variants in 141 individuals, including 35 with recurrent dominant pathogenic variants and 91 affected members from 73 families with biallelic variants. Recessive RNU2-2 NDD is at least twice as frequent as the dominant form and often involves a de novo variant in trans with an inherited allele, consistent with the high mutability of snRNA genes. Dominant and recessive RNU2-2 NDDs share overlapping clinical features, with frequent epilepsy. Blood transcriptomics and DNA methylation analyses revealed subtle, variant-specific effects on splicing and episignatures. Our results support a gradient-of-impact model bridging dominant and recessive inheritance, and establish RNU2-2 variants as a principal contributor to NDDs, nearly as prevalent as ReNU syndrome.


  • DNA methylation signature and clinical delineation of PACS1-related disorder in 24 unreported individuals

    by Quentin Sabbagh, Camille Cenni, Sadegheh Haghshenas, Jean-Luc Alessandri, Mads Bak, Allan Bayat, Mouna Barat-Houari, Alfredo Brusco, Tiffany Busa, Anaïs Calaya, et al.

    PACS1-related disorder (PACS1-RD), also known as Schuurs-Hoeijmakers syndrome, is a rare autosomal dominant neurodevelopmental disorder predominantly caused by the recurrent de novo c.607 C > T p.(Arg203Trp) gain-of-function variant. Although core clinical features have been delineated, systematic data on developmental milestones, growth parameters, and clinical variability remain limited. We assembled a series of 24 previously unreported, unrelated individuals with PACS1-RD and compared their clinical and molecular features with 84 individuals from the literature. Genome-wide DNA methylation profiling was performed on peripheral blood DNA using bisulfite sequencing, interrogating ~860,000 CpG sites. Our study expands the phenotypic spectrum of PACS1-RD by reporting median age at independent walking and first spoken words (both 24 months), cross-sectional growth parameters, and previously undescribed clinical features, including congenital kidney malformations (25%) and feeding difficulties (75%). Compared with the literature, our series showed a higher prevalence of cryptorchidism (77.8%), congenital heart defect (45.8%), and hypotonia (75%). Methylation analysis identified a specific episignature for PACS1-RD, consistently observed in individuals carrying either the canonical p.(Arg203Trp) or the non-recurrent p.(Arg203Gln) variant. This episignature further enabled PACS1-RD diagnosis in one unsolved individual initially suspected of Kabuki syndrome. These findings refine the clinical delineation of PACS1-RD and establish an episignature that will support diagnosis in unresolved neurodevelopmental disorders and guide pathogenicity assessment of non-recurrent PACS1 variants.


  • Open Access

    Non-coding genome in nail-patella syndrome: Genetic diagnosis as a guide for personalized follow-up

    by Perrine Brunelle, Anne-Sophie Jourdain, Fabienne Escande, Séverine Audebert-Bellanger, Sonia Bouquillon, Valérie Cormier-Daire, Alexandra Desdoits, Didier Lacombe, Arnaud Molin, Nicolas Gruchy, et al.

    Limb malformations are paradigmatic of altered gene regulation in human disease. Nail-Patella Syndrome (NPS) is a rare condition characterized mainly by skeletal defects, glomerulonephritis and glaucoma, with variable expressivity. NPS is caused by the haploinsufficiency or loss-of-function of LMX1B , which encodes a transcription factor involved in limb dorsalization, in the renal glomerular filtration barrier and the anterior segment of the eye. The dorsal expression of LMX1B in the developing limbs is under the control of LMX1B autoregulatory modules (LARMs), which are non-coding cis -regulatory elements (CREs) with a limb-specific enhancer activity. Here, we describe the regulatory landscape and report regulatory anomalies at the LMX1B locus in four families, including the deletion of a CRE, two structural variations disrupting the CRE-promoter interaction, and a 5’UTR variant causing an upstream open reading frame (ORF). Molecular mechanisms involving the non-coding genome can have a tissue-specific impact on gene expression, resulting in incomplete forms of the syndrome, and sometimes modifying its classical mode of inheritance. While approximately 95% of individuals with NPS carry pathogenic variants in the coding regions of LMX1B , non-coding alterations explain the remaining cases. This work highlights the importance of genomic diagnosis (gene ORF versus CRE alteration) for precision medicine and genetic counselling in rare diseases.


  • Open Access

    Resin Infiltration for the Management of Hypomature Amelogenesis Imperfecta: A Case Report

    by Elsa Garot, Julia Estivals, Ana Ribeiro, Anais Cavaré, Olivia Kérourédan, Julien Van Gils

    Objective: We are aimed at describing the clinical and psychosocial benefits of resin infiltration as a minimally invasive treatment option for hypomature amelogenesis imperfecta in a child. Hypomature amelogenesis imperfecta is a rare hereditary enamel defect that significantly compromises dental esthetics, function, and psychosocial well‐being. Conventional management often involves invasive restorative approaches such as composites, veneers, or crowns, which may require removal of sound tooth tissue and pose challenges in pediatric patients. Clinical Considerations: An 11‐year‐old girl presenting with hypomature amelogenesis imperfecta and severe esthetic concerns associated with impaired oral health–related quality of life was treated using an erosion infiltration technique with resin (Icon, DMG). Following enamel surface conditioning, a low‐viscosity resin infiltrant was applied to penetrate and mask hypomature enamel opacities. The procedure led to immediate and significant esthetic improvement, with enhanced enamel translucency and high patient satisfaction. Esthetic outcomes remained stable over a 3‐year follow‐up period, including during orthodontic treatment, and were associated with a marked improvement in oral health–related quality of life. Conclusions: This case highlights the potential of resin infiltration to offer a conservative alternative to conventional restorative methods in hypomature amelogenesis imperfecta, with meaningful improvement in dental esthetics and oral health–related quality of life. Nevertheless, further clinical studies and long‐term follow‐up are required to validate its durability and to establish standardized treatment protocols.

  • Comprehensive analysis of CNOT3-related neurodevelopmental disorders: phenotypic and genotypic characterization

    by Camille Engel, Michaela Rendek, Jessica Assoumani, Emanuela Argilli, Francesca Ariani, Anne-Laude Avice-Denizet, Emilia K. Bijlsmaa, Pierre Blanc, Lucia Pia Bruno, Bert Callewaert, et al.

    The CCR4-NOT complex, crucial in gene expression regulation, includes CNOT3, a subunit linked to neurodevelopmental disorders when mutated. This study investigates 51 patients from 42 families with heterozygous CNOT3 variants, aiming to expand the understanding of CNOT3-related neurodevelopmental disorders and explore genotype-phenotype correlations. Patients originated from various countries, reflecting the disorder’s global significance. All patients exhibited developmental delays, particularly in the language area. Intellectual disability was found in 87% of patients and was typically mild to moderate. Behavioral issues, including autism spectrum disorders and attention deficits, were common, affecting over half of the patients. Dysmorphic features were highlighted and may help establishing the diagnosis. Epilepsy was uncommon (10%). Twenty-eight novel variants were identified, including missense, nonsense, frameshift, intronic variations and a deletion of 12 exons. Missense variants clustered at the N- and C-terminal regions of the protein, indicating critical functional roles. No clear genotype-phenotype correlation was observed, suggesting that all identified variants resulted in a loss-of-function effect. Finally, this work delineates the clinical and molecular spectrum of CNOT3-related disorders thanks to an in-depth characterization of a large cohort. Further research will be necessary to understand the functional consequences of the variants and enhance patient long-term outcomes.


  • Top Cited Papers
    Open Access

    Dominant variants in major spliceosome U4 and U5 small nuclear RNA genes cause neurodevelopmental disorders through splicing disruption

    by Caroline Nava, Benjamin Cogne, Amandine Santini, Elsa Leitão, François Lecoquierre, Yuyang Chen, Sarah L. Stenton, Thomas Besnard, Solveig Heide, Sarah Baer, et al.

    The major spliceosome contains five small nuclear RNAs (snRNAs; U1, U2, U4, U5 and U6) essential for splicing. Variants in RNU4-2, encoding U4, cause a neurodevelopmental disorder called ReNU syndrome. We investigated de novo variants in 50 snRNA-encoding genes in a French cohort of 23,649 individuals with rare disorders and gathered additional cases through international collaborations. Altogether, we identified 145 previously unreported probands with (likely) pathogenic variants in RNU4-2 and 21 individuals with de novo and/or recurrent variants in RNU5B-1 and RNU5A-1, encoding U5. Pathogenic variants typically arose de novo on the maternal allele and cluster in regions critical for splicing. RNU4-2 variants mainly localize to two structures, the stem III and T-loop/quasi-pseudoknot, which position the U6 ACAGAGA box for 5′ splice site recognition and associate with different phenotypic severity. RNU4-2 variants result in specific defects in alternative 5′ splice site usage and methylation patterns (episignatures) that correlate with variant location and clinical severity. This study establishes RNU5B-1 as a neurodevelopmental disorder gene, suggests RNU5A-1 as a strong candidate and highlights the role of de novo variants in snRNAs.


  • Open Access

    Neurofibromatosis-Noonan syndrome: a prospective monocentric study of 26 patients and literature review

    by Didier Bessis, Dominique Vidaud, Pierre Meyer, Laurence Pacot, de La Villeon G, Adeline Alice Bonnard, Yline Capri, Christine Coubes, Fanchon Herman, Didier Lacombe, et al.

    Background: Data on clinical manifestations of neurofibromatosis-Noonan syndrome (NF-NS) remain heterogeneous, with limited validated descriptions. Methods: This study aims to better define the clinical and molecular features of NF-NS and compare them with existing literature. Secondary objectives include evaluating inter-rater diagnostic agreement among experienced clinicians and assessing the utility of deep-learning algorithms (Face2Gene® [F2G]). Additionally, we assess the prevalence of congenital heart malformations (CHM) in NF-NS compared to ‘classic’ neurofibromatosis type 1 (NF1). A 9-year, prospective, monocentric study was conducted, involving patients with NF1 pathogenic variants (PVs) and Noonan syndrome-like facial phenotype (NSLFP). Results: Twenty-six patients were enrolled. NSLFP was categorized as ‘suggestive’ in 69% of cases and ‘typical’ in 31%. The presence of at least two facial abnormalities (e.g., low-set ears, downslanted palpebral fissures, hypertelorism, and ptosis) was consistently observed in ‘typical’ cases. Inter-rater concordance was substantial (0.65 [95% CI = 0.56; 0.74]), while concordance between clinicians and F2G was almost perfect at (0.821 [CI 95% = 0.625; 1.000]). Missense NF1 PVs were observed in 38.5% of cases. Apart from NSLP and a high frequency of pectus excavatum (62.5%), no significant differences in anthropometric, dermatological, neurological, skeletal, or ocular clinical features were observed between NF-NS and ‘classic’ NF1. CHM were found in 19.2% of NF-NS patients, with pulmonic stenosis present in 7.7%. Conclusion: NF-NS is a distinct phenotypic variant of NF1, marked by NSLP with consistent facial features -, and frequent pectus excavatum. F2G demonstrated high diagnostic concordance, reinforcing its clinical utility. Given the elevated risk of CHM, especially pulmonic stenosis, proactive cardiovascular assessment similar to other RASopathies is recommended for NS-NF patients, regardless of NF1 PV type.


  • Open Access

    Transcriptome and acetylome profiling identify crucial steps of neuronal differentiation in Rubinstein-Taybi syndrome

    by Julien Van Gils, Slim Karkar, Aurélien Barre, Seyta Ley-Ngardigal, Sophie Nothof, Stéphane Claverol, Caroline Tokarski, Jean-Philippe Trani, Raphael Chevalier, Natacha Broucqsault, et al.

    Rubinstein-Taybi syndrome (RTS) is a rare and severe genetic developmental disorder characterized by multiple congenital anomalies and intellectual disability. CREBBP and EP300, the two genes known to cause RTS encode transcriptional coactivators with a catalytic lysine acetyltransferase (KAT) activity. Loss of CBP or p300 function results in a deficit in protein acetylation, in particular at histones. In RTS, nothing is known on the consequences of the loss of histone acetylation on the transcriptomic profiles during neuronal differentiation. To address this question, we differentiated induced pluripotent stem cells from RTS patients carrying a recurrent CREBBP mutation that inactivates the KAT domain into cortical and pyramidal neurons. By comparing their acetylome and their transcriptome at different neuronal differentiation time points, we identified 25 specific acetylated histone residues altered in RTS. We also identified the transition between neural progenitors and immature neurons as a critical step of the differentiation process, with a delayed neuronal maturation in RTS. Overall, this study opens new perspectives in the definition of epigenetic biomarkers for RTS, whose methodology could be extended to other chromatinopathies.